Quantcast

LEGAL NEWSLINE

Sunday, April 28, 2024

NELSON MULLINS RILEY & SCARBOROUGH: Life Sciences Regulatory Attorney Christopher Hanson Joins Nelson Mullins in D.C.

H

Nelson Mullins Riley & Scarborough LLP issued the following announcement on Apr. 21.

Life sciences regulatory attorney Christopher J. Hanson has joined Nelson Mullins Riley & Scarborough LLP in its Washington, D.C. office as a partner. He joins from Covington & Burling LLP, where he was a special counsel. 

Hanson assists clients in tackling their most sophisticated and high-stakes regulatory issues involving medical devices, in vitro diagnostics, clinical laboratories, human and animal drugs, cosmetics, and radiation-emitting electronic products. He represents product manufacturers as well as industry groups seeking input into regulatory rulemakings and policies and drafting life sciences legislation. He also has experience preparing regulatory product submissions, responding to agency enforcement actions, and conducting global internal investigations and audits.

“Christopher has significant experience working with the U.S. Food and Drug Administration, the Centers for Medicare & Medicaid Services, and the Federal Trade Commission,” said Jennifer Mallory, who leads the FDA Regulatory Compliance & Litigation Group. “He brings additional depth to our services, especially those offered to our clients in the medical device, in vitro diagnostics, and clinical laboratory spaces. We are delighted to welcome Christopher to our group that shares Christopher’s commitment to crafting creative and practical solutions for clients regulated by FDA, CMS, and the FTC.”

Hanson earned his J.D. from Northwestern University School of Law, a Master of Divinity from Harvard University, and a B.A. from Yale University.

The Nelson Mullins FDA Compliance and Litigation Team represents FDA-regulated industries, advising general counsels, executives, clinical research professionals, physicians, and other healthcare providers. The team includes lawyers, pharmacists, and nurse consultants who have worked in the public and private sectors and developed an understanding of the real issues that clients face when navigating the FDA regulatory scheme.

Original source can be found here.

ORGANIZATIONS IN THIS STORY

More News